The APAF1 Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-mediated polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted gene disruption of APAF1. This heterogeneous cell pool contains a variety of loss-of-function mutations across the target locus, providing a model to study apoptosis signaling in the absence of functional APAF1. The polyclonal format captures diverse genetic perturbations, enabling robust experimental analysis and functional validation.
The A-549 host cell line is a human lung adenocarcinoma model established from a 58-year-old male, widely used for non-small cell lung cancer research. These adherent epithelial cells harbor a mutated KRAS oncogene and functional TP53 pathway, making them relevant for apoptosis and chemoresistance studies. The cell line’s well-characterized signaling and genetic tractability make it an ideal background for knockout models studying cancer survival pathways.
APAF1 encodes the apoptotic protease activating factor 1, the central adaptor of the intrinsic apoptotic pathway. Upon mitochondrial cytochrome c release, APAF1 oligomerizes into the apoptosome, recruiting procaspase-9 (CASP9) for autocatalytic activation, which then cleaves executioner caspases-3 and -7. Upstream, APAF1 is activated by TP53 and E2F1 in response to DNA damage, and is inhibited by XIAP and HSPA1A/HSP70; assembly is modulated by APIP. The balance of BAX and BCL2 controls cytochrome c mobilization, and chemotherapeutics like cisplatin induce this cascade, positioning APAF1 as a critical apoptotic node.
In the A-549 lung adenocarcinoma model, APAF1 knockout provides a powerful system to investigate apoptosis resistance that underlies tumor progression and treatment failure. These cells enable precise dissection of how APAF1 loss impacts drug sensitivity, DNA damage response, and cellular survival signaling. Researchers can identify alternative cell death pathways that compensate for APAF1 deficiency, potentially unveiling new therapeutic targets for lung cancer.
These knockout cells support apoptosis pathway validation, drug screening, and apoptosome research using techniques such as Western blotting for cleaved caspase-3, quantitative RT-PCR, cytochrome c release assays, and caspase-9 activity measurements. Co-immunoprecipitation and RNA-seq further elucidate signaling networks. The polyclonal population ensures representation of multiple editing events, enhancing statistical power. Please contact Ascent Research for more information.
